The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $800,005 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to advance the understanding of how genetic variants in G-protein coupled receptors (GPCRs) contribute to autoimmune diseases. The key objectives of this 5-year project are to: 1) Define the structural basis for impaired function of the...
This $2,483,910 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support three integrated projects at The Washington University focused on defining novel disease mechanisms related to genetic errors of immunity (GEIs). The first project will map genes prone to autosomal random monoallelic expression (ARMAE) in the immune system and evaluate the epigenetic regulation of this...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $138,051 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The objective of this 2-year research project is to understand the role of thymic B cells in T cell tolerance and autoimmune disease pathogenesis. The research aims to investigate how type-III interferon drives thymic B cell licensing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $182,520.00 to Dr. Nikolaos Skartsis at Mayo Clinic College of Medicine and Science for a 5-year research project focused on understanding the impact of inflammatory signals on regulatory T cells (Tregs). The central hypothesis is that Tregs can respond positively to pro-inflammatory cytokines by stabilizing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,504,225.00 to Mayo Clinic to develop engineered mesenchymal stromal cells (MSCs) with enhanced immunosuppressive and trafficking capabilities for the treatment of graft-versus-host disease (GVHD) and inflammatory bowel disease (IBD). The key objectives are to: 1) Determine the mechanisms by which the...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), provides $580,274 to HMH Hospitals Corporation (dba Hackensack University Medical Center) for research on celiac disease and inflammatory bowel diseases. The project aims to elucidate the genotype-phenotype relationships and underlying genetic and epigenetic mechanisms that contribute to these prevalent gastrointestinal disorders. Key...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $737,502 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The grant, titled "Role of WDFY4 in Treg Development," will fund research to investigate a novel pathway involving the WDFY4 protein that regulates antigen presentation by dendritic cells and is critical for the development and function of regulatory T cells (Tregs). The...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research focused on understanding how CD4+ T cells respond to food peptides and their role in celiac disease. The $553,342 award, with a project period from November 18, 2024 to October 31, 2029, will enable the Regents of the University of Minnesota to use gene knockout and cell transfer...
This Project Grant award, with a total funding amount of $221,888, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this 23-month research project is to explore mechanisms for inducing apoptosis (programmed cell death) in Th17 cells, which play a pathogenic role in many inflammatory and autoimmune diseases. The research will investigate targeting the IRE1 and STAT3...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is funding a vaccine immunogenetics research program focused on identifying genetic and phenotypic determinants of the immune response to COVID-19 infection and vaccination. The $814,873 award, with a period of performance from Aug 1, 2024 to Jul 31, 2029, will support a comprehensive genome-wide association study and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research provides $2,364,292 to Mayo Clinic to study the genetic mechanisms driving immunoglobulin G4-related disease (IgG4-RD), a rare autoimmune condition. The 5-year award, beginning July 5, 2024, supports a two-pronged approach to understand how specific gene variants in the UBR4 and IKZF1 genes disrupt immune tolerance and lead to excessive T-helper 2 (Th2) cell polarization, a key driver of IgG4-RD. The research aims to elucidate the molecular pathways by which these genetic variants alter T cell receptor signaling and Th2 differentiation, with the goal of identifying potential therapeutic targets. The project also seeks to evaluate whether the identified biomarkers have broader implications for non-familial IgG4-RD and other Th2-mediated diseases. This work leverages Mayo Clinic's expertise in monogenic autoimmune disorders and advanced translational research capabilities.